Chemodex

Anastrozole

As low as CHF 84.00
In stock
Only %1 left
CDX-A0802-M500500 mgCHF 84.00
CDX-A0802-G0011 gCHF 135.00
NEW
 
More Information
Product Details
Synonyms Anastrol; ICI-D 1033; ZD 1033; α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Product Type Chemical
Properties
Formula C17H19N5
MW 293.37
CAS 120511-73-1
RTECS CZ1465000
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance White crystalline powder.
Solubility Soluble in DMF (10 mg/ml), DMSO (10 mg/ml), ethanol (20 mg/ml), methanol or chloroform.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key YBBLVLTVTVSKRW-UHFFFAOYSA-N
Smiles CC(C)(C#N)C1=CC(CN2C=NC=N2)=CC(C(C)(C)C#N)=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
Product Specification Sheet
Datasheet Download PDF
Description

Anastrozole is a highly potent, non-steroidal aromatase inhibitor that selectively inhibits the aromatase enzyme (CYP19A1) responsible for converting androgens to estrogens. With an IC50 in the low nanomolar range (typically ~15 nM), it effectively suppresses estrogen synthesis, making it a key compound in hormone-related cancer research. It is selective for aromatase/CYP19A1 over the cytochrome P450 (CYP) isoforms CYP1A2, CYP2A6, CYP2C9, CYP2D6, and CYP3A. Anastrozole is widely used in studies of estrogen receptor-positive (ER+) breast cancer, endocrine resistance and hormone regulation. It is a standard reference compound in preclinical drug screening and mechanistic studies targeting estrogen biosynthesis. Compound can be used as analytical reference material in relation to doping analytics.

Product References
(1) P.V. Plourde, et al.; Breast Cancer Res. Treat. 30(1), 103-111 (1994) | (2) S.W. Grimm & M.C. Dyroff; Drug Metab. Dispos. 25, 598 (1997) | (3) P.E. Goss & L.M. Tye; Oncology 11, 1697 (1997) | (4) P.E. Lonning, et al.; Breast Cancer Res. Treat. 49, S53 (1998) | (5) A.U. Buzdar; Br. J. Cancer 85, 6 (2001) | (6) P. Kubatka, et al.; Anticancer Res. 28, 28193 (2008) | (7) J. Cairns, et al.; Mol. Cancer Ther. 21, 206 (2022) | (8) O. Alomar, et al.; Clin. Ther. 44, 1214 (2022) | (9) J. Sternberg, et al.; Metabolites 15, 452 (2025)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.